alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-2-氟-苯乙酸 | 161330-30-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-2-氟-苯乙酸
• 中文别名: N-BOC-DL-2-氟苯甘氨酸
• 英文名称: 2-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)acetic acid
• 英文别名: [(Tert-butoxycarbonyl)amino](2-fluorophenyl)acetic acid；2-(2-fluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid
• CAS: 161330-30-9
• 化学式: C₁₃H₁₆FNO₄
• 分子量: 269.273
• InChiKey: IUFATHQIUYUCFE-UHFFFAOYSA-N

物化性质

• 沸点：
  403.5±40.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-BOC-(2-Fluorophenyl)glycine
{[(tert-butoxy)carbonyl]amino}(2-fluorophenyl)acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-BOC-(2-Fluorophenyl)glycine
CAS number: 161330-30-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H16FNO4
Molecular weight: 269.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-2-氟-苯乙酸 在 N-溴代丁二酰亚胺(NBS) 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 水 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 6.0h， 生成 3-[[4-[[8-Tert-butyl-2-(2-fluorophenyl)-3-oxo-1,4-diazaspiro[4.5]dec-1-en-4-yl]methyl]benzoyl]amino]propanoic acid
  参考文献：
  名称：

  The Discovery of N-((2H-Tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist

  摘要：

  A novel series of spiroimidazolone-based antagonists of the human glucagon receptor (hGCGR) has been developed. Our efforts have led to compound 1, N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822), a potent hGCGR antagonist with exceptional selectivity over the human glucagon-like peptide-1 receptor. Oral administration of 1 lowered 24 h nonfasting glucose levels in imprinting control region mice on a high fat diet with diet-induced obesity following single oral doses of 3 and 10 mg/kg. Furthermore, compound 1, when dosed orally, was found to decrease fasting blood glucose at 30 mg/kg in a streptozotocin-treated, diet-induced obesity mouse pharmacodynamic assay and blunt exogenous glucagon-stimulated glucose excursion in prediabetic mice.

  DOI：

  10.1021/jm401858f
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 2-氟-DL-Α-苯基甘氨酸 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.5h， 以100%的产率得到alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-2-氟-苯乙酸
  参考文献：
  名称：

  使用Staudinger反应固相合成β-内酰胺，通过19 F NMR光谱监测

  摘要：

  我们报告了使用19 F NMR作为监测固相反应的简单方法。在涉及氟化α-氨基酯，醛和酰氯的多组分反应的情况下，描述了包括保护，偶联，脱保护，缩合，环加成和裂解步骤在内的多步骤序列。

  DOI：

  10.1016/s0040-4020(03)00553-2

文献信息

• [EN] GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE GLYCINE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES
  申请人：CHIESI FARMA SPA

  公开号：WO2012069275A1

  公开（公告）日：2012-05-31

  The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

  本发明涉及作为肌碱受体拮抗剂的生物碱氨酯衍生物，其制备方法，包含它们的组合物以及它们的治疗用途。
• GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF
  申请人：AMARI Gabriele

  公开号：US20120134934A1

  公开（公告）日：2012-05-31

  Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.

  生物碱氨酯衍生物根据式(I)和(VI)作为肌碱受体拮抗剂。
• Amino Acids and Peptides. XXIII. Leu-Enkephalin Analogs Containing a Fluorinated Amino Acid at Position 2, 4 or 5.
  作者：Mitsuko MAEDA、Koichi KAWASAKI、Takeo TAGUCHI、Yoshiro KOBAYASHI、Yoshihiro YAMAMOTO、Kazuhiro SHIMOKAWA、Masakatsu TAKAHASHI、Kaoru NAKAO、Hiroshi KANETO

  DOI：10.1248/cpb.42.1658

  日期：——

  Fluorinated analogs of Leu-enkephalin were synthesized by the solution method and the solid-phase method. The synthetic peptides were examined for opioid activities on mouse vas deferens and guinea pig ileum. Among the synthetic peptides, [D-Ala2, Leu(F3)(2R, 4S)5]enkephalin and [D-Ala2, Leu(F3)(2S, 4R)5]enkephalin exhibited potent opioid activity, and [Leu(F3)(2S, 4R)5]enkephalin exhibited high δ-receptor selectivity.

  氟化的Leu-内啡肽类似物通过溶液法和固相法合成。合成的肽在小鼠输精管和豚鼠回肠中进行了阿片活性测试。在合成的肽中，[D-Ala2, Leu(F3)(2R, 4S)5]内啡肽和[D-Ala2, Leu(F3)(2S, 4R)5]内啡肽表现出强效的阿片活性，而[Leu(F3)(2S, 4R)5]内啡肽则表现出较高的δ-受体选择性。
• [EN] HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DÉRIVÉS HÉTÉROARYLE POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
  申请人：CHIESI FARMA SPA

  公开号：WO2015082616A1

  公开（公告）日：2015-06-11

  The invention relates to novel compounds of formula (I) which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

  本发明涉及一种新型化合物，其化学式为(I)，既是磷酸二酯酶4（PDE4）酶抑制剂又是肌碱M3受体拮抗剂，以及制备这种化合物的方法、含有它们的组合物以及其治疗用途。
• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRAZINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018136661A1

  公开（公告）日：2018-07-26

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了Formula I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4在规范中给出的含义，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。